The novel coronavirus disease-19 (COVID-19) pandemic triggered a national emergency declaration in the United States on March 13, 2020. The resultant diversion of healthcare and public attention toward disease exposure avoidance, propagated a concerning reduction in emergency department (ED) presentations for many serious medical conditions.[@bib0001] Urinary stone disease (USD) is a frequent cause of ED visits and can be life or organ threatening if not treated in a timely manner.[@bib0002] One small Italian study showed that the pandemic had no effect on USD emergency presentation rates[@bib0003] but its effect in a larger US cohort remains unknown.

Following Institutional Board Review approval, we analyzed all primary USD presentations to the Cleveland Clinic ED of 4 large hospital campuses (Main Campus, Fairview, Avon, Hillcrest) serving the wider Cleveland Area during the current "COVID-era" (March 16-April 30, 2020) and compared this with an equivalent "Pre-COVID era" from exactly a year ago (March 16-April 30, 2019). We analyzed baseline clinical characteristics at ED presentation and subsequent stone management.

During the COVID-era, there was a 36% reduction in emergent USD presentations compared to an equivalent pre-COVID era. Interestingly, there was no difference in baseline characteristics or clinical severity at presentation (measured by systemic inflammatory response syndrome criteria, serum creatinine, urinary tract infection or need for emergent intervention; [Table 1](#tbl0001){ref-type="table"} ). However, a higher proportion of COVID-era patients did have evidence of acute kidney injury (AKI) based on RIFLE classification[@bib0004] (4.7% vs 2.6%) potentially suggestive of a delay in presentation.Table 1Comparison of characteristics of patients presenting to Cleveland area emergency departments with a primary stone diagnosis during a pre-COVID Era (March 16-April 30, 2019) and a COVID era (March 16-April 30, 2020)Table 1Pre-COVID EraCOVID Era*P* ValueTotal ED presentations269172N/a**Initial ED presentation characteristics**Age[†](#tb1fn2){ref-type="table-fn"}51.3 (18-93)52.6 (18-93).4454[§](#tb1fn4){ref-type="table-fn"}Sex[‡](#tb1fn3){ref-type="table-fn"}.4003[║](#tb1fn5){ref-type="table-fn"} Male147 (55%)101 (59%) Female122 (45%)71 (41%)Race[‡](#tb1fn3){ref-type="table-fn"}.1464[║](#tb1fn5){ref-type="table-fn"} White216 (80%)148 (86%) Black25 (9%)9 (5%) Mixed/Other23 (9%)9 (5%) Unknown5 (2%)6 (4%)BMI (kg/m^2^)[†](#tb1fn2){ref-type="table-fn"}30.8 (17-62)30.3 (18-56).4197[§](#tb1fn4){ref-type="table-fn"}MyChart use[‡](#tb1fn3){ref-type="table-fn"}.4796[║](#tb1fn5){ref-type="table-fn"} User179 (66.5%)120 (70%) Non user90 (33.5%)52 (30%)Prior stone history[‡](#tb1fn3){ref-type="table-fn"}.2438[║](#tb1fn5){ref-type="table-fn"} Yes131 (49%)74 (43%) No138 (51%)98 (57%)Maximum stone diameter (mm)[†](#tb1fn2){ref-type="table-fn"}5.2 (1-30)4.5 (1-18)[\*](#tb1fn1){ref-type="table-fn"}.0296[§](#tb1fn4){ref-type="table-fn"}Imaging modality[‡](#tb1fn3){ref-type="table-fn"}.3963[║](#tb1fn5){ref-type="table-fn"} CT255 (95%)164 (95.3%) US14 (5%)7 (4.1%) X-ray01 (0.6%)Stone laterality[‡](#tb1fn3){ref-type="table-fn"}[\*](#tb1fn1){ref-type="table-fn"}.02[║](#tb1fn5){ref-type="table-fn"} Right119 (44%)98 (57%) Left140 (52%)71 (41%) Bilateral10 (4%)3 (2%)Stone location[‡](#tb1fn3){ref-type="table-fn"}.2544[║](#tb1fn5){ref-type="table-fn"} Kidney21 (8%)14 (8%) UPJ20 (7.4%)6 (3.5%) Proximal ureter63 (23.4%)37 (21.5%) Mid ureter30 (11.2%)14 (8%) Distal ureter/UVJ135 (50%)101 (59%)SIRS criteria at presentation[‡](#tb1fn3){ref-type="table-fn"}.1162[║](#tb1fn5){ref-type="table-fn"} 0156 (58%)84 (49%) 184 (31%)71 (41%) 224 (9%)16 (9%) 35 (2%)1 (1%) 400Serum creatinine at presentation (mg/dL)[†](#tb1fn2){ref-type="table-fn"}0.99 (0.23-3.2)1.00 (0.55-4.4).4284[§](#tb1fn4){ref-type="table-fn"}Evidence of AKI[‡](#tb1fn3){ref-type="table-fn"}^,^[¶](#tb1fn6){ref-type="table-fn"}7 (2.6%)8 (4.7%)N/aPositive urine culture (\>10,000 CFU/mL)[‡](#tb1fn2){ref-type="table-fn"}20 (7%)12 (7%)N/aEmergent intervention[‡](#tb1fn3){ref-type="table-fn"}49 (18%)37 (22%).0987[║](#tb1fn5){ref-type="table-fn"} Stent3020 Nephrostomy tube82 SWL42 URS713**Post-ED management**Immediate ED management[‡](#tb1fn3){ref-type="table-fn"}.3984[║](#tb1fn5){ref-type="table-fn"} Conservative27 (10%)14 (8.2%) Conservative with MET180 (67%)109 (63.4%) Admission62 (23%)49 (28.4%)ICU admissions[‡](#tb1fn2){ref-type="table-fn"}3 (1%)0Time to clinic visit (days)[†](#tb1fn2){ref-type="table-fn"}7 (0-64)15 (0-76)[\*](#tb1fn1){ref-type="table-fn"}\<.0001[§](#tb1fn4){ref-type="table-fn"}Types of visit[‡](#tb1fn3){ref-type="table-fn"} Total11565 In-person115 (100%)4 (6%) Virtual visit058 (89%) Telephone03 (5%)[\*](#tb1fn1){ref-type="table-fn"}\<.0001[║](#tb1fn5){ref-type="table-fn"}Time to definitive management (days)[†](#tb1fn2){ref-type="table-fn"}17 (0-82)20 (0-86).2545[§](#tb1fn4){ref-type="table-fn"}Definitive management[‡](#tb1fn3){ref-type="table-fn"}[\*](#tb1fn1){ref-type="table-fn"}.0130[║](#tb1fn5){ref-type="table-fn"} Awaiting07 (4%) Observation20 (7%)9 (5%) Stone passage150 (56%)104 (60%) URS79 (29%)43 (25%) SWL15 (6%)7 (4%) PCNL5 (2%)1 (1%) Nephrectomy01 (1%)Postoperative stent management[‡](#tb1fn3){ref-type="table-fn"}[\*](#tb1fn1){ref-type="table-fn"}\<.0001[║](#tb1fn5){ref-type="table-fn"} No stent10 (12%)29 (66%) Stent65 (77%)8 (18%) Stent with string6 (7%)7 (16%) Nephrostomy tube3 (4%)0[^1][^2][^3][^4][^5][^6][^7]

The COVID-era resulted in a measurable shift in subsequent patient management. There were significant delays having a Urology clinic visit (mean 15 days vs 7 days pre-COVID, *P* \< .0001) and a seismic shift toward these being virtual or telephone visits (from 0% to 94%) despite availability of this technology during both periods. Given most stone cases require prompt management to avoid a sequelae of complications, this delay did not affect the time to receive definitive management which is in part due to the structured Cleveland Clinic Operative Tier system created to stratify urology cases based on emergent need during the pandemic.[@bib0005] For those undergoing ureteroscopy or percutaneous nephrolithotomy, where postprocedure ureteral stent placement is common, we found a considerable practice shift toward not leaving stents (12%-66%) and also more stents left with a string (7%-16%), both removing a further patient encounter for stent removal, in addition to eliminating potential COVID exposure risk. Of note, none of these patients had a subsequent ED visit or resultant complication suggestive of this being a suitable future management change consideration for appropriate patients.

To our knowledge, this represents the first US-based analysis of the effect of the pandemic on USD presentations and highlighted a measurable reduction in ED presentations with higher rates of AKI and also interesting changes in Urology practice management patterns. With the pandemic still raging on with no clear end in sight, the true impact this will have on our stone clinical practice remains to be fully determined.
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[^1]: AKI, acute kidney injury; BMI, body mass index; CT, computed tomography; ED, emergency department; ICU, intensive care unit; MET, medical expulsive therapy; PCNL, percutaneous nephrolithotomy; SIRS, systemic inflammatory response syndrome; SWL, shockwave lithotripsy; UPJ, uretero-pelvic; URS, ureteroscopy; US, ultrasound; UVJ, uretero-vesical junction.

[^2]: Statistically significant difference.

[^3]: Mean (range in brackets).

[^4]: Number(percentage in brackets).

[^5]: *t* test.

[^6]: Chi-square test.

[^7]: Acute kidney injury defined as a \>1.5 times increase in creatinine from baseline.
